Related Experiment Videos
Hepatitis B vaccination in acute lymphoblastic leukemia
1Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Leukemia Research
|May 21, 1998
Summary
Hepatitis B vaccination in acute lymphoblastic leukemia patients showed low antibody response. Immunosuppression from disease and treatment likely reduces vaccine effectiveness, suggesting alternative prophylaxis may be needed.
Area of Science:
- Hepatology
- Immunology
- Oncology
Background:
- Hepatitis B virus (HBV) infection poses a risk to patients with acute lymphoblastic leukemia (ALL).
- Immunosuppression in ALL patients, due to disease and chemotherapy, may impair vaccine response.
Purpose of the Study:
- To assess the efficacy of active immunization against HBV in ALL patients.
- To evaluate antibody response to a recombinant DNA hepatitis B vaccine in this population.
Main Methods:
- 162 ALL patients received a three-dose recombinant DNA HBV vaccine regimen (0, 1, 2 months) plus a booster.
- Antibody titers to hepatitis B surface antigen were measured post-vaccination.
Main Results:
- Only 19.7% of patients developed detectable antibodies to hepatitis B surface antigen.
- A protective antibody titer was achieved in merely 10.5% of vaccinated patients.
- Low response rates suggest diminished vaccine efficacy in ALL patients.
Conclusions:
- Active immunization with recombinant DNA HBV vaccine is poorly effective in ALL patients.
- Disease and treatment-induced immunosuppression significantly impair vaccine responsiveness.
- Passive-active prophylaxis (vaccine plus immunoglobulin) may offer a more effective strategy for HBV protection in ALL patients.